Programs

A focused pipeline
for durable cures.

We are advancing a portfolio of CRISPR-based investigational therapies against viral diseases where persistence remains the central challenge.

Our approach

Start with the biology. Scale with discipline.

Each program is built around a clear viral target, a defined patient need and a development path that balances ambition with evidence.

CodeProgramIndicationStage
EBT-101

HIV cure research

HIV-1 infectionClinical research
EBT-201

Viral reservoir program

Chronic viral diseasePreclinical
EBT-301

Next-generation editing

Emerging targetsDiscovery
Development path

Every milestone is a promise to keep testing.

Define the target

Map the viral reservoir and identify sequences where precision editing could have the greatest therapeutic value.

Prove the mechanism

Test editing, selectivity and durability in a cascade of models designed to answer the hard questions early.

Translate to patients

Move with care into clinical development, measuring the outcomes that matter to people—not just to assays.

Stay informed

Progress worth following.

Read the latest updates from our research, leadership and company.

Read the news